HighGravityDataBioMarin Pharmaceutical — Aug 6, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-26-000015
Showing in the filing
Total Revenues Midpoint Growth (Y/Y)
“21%”
Period
FY2026
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 22
VOXZOGO full-year 2026 revenue (CEO quote) for FY2026
“at least $1 billion”
Peak revenue for GALAFOLD for FY2030
“approximately $1.4 billion”
Peak revenue for POMBILITI + OPFOLDA for FY2030
“approximately $1.2 billion”
Cost reductions from Amicus acquisition (GAA… for FY2028
“approximately $280 million”
Cost reductions on a GAAP basis for FY2028
“approximately $280 million”
Cost reductions from Amicus acquisition (Non… for FY2028
“approximately $220 million”
GALAFOLD and POMBILITI + OPFOLDA, combined, … for FY2030
“over 60%”
Gross leverage target for FY2027
“below 2.5 times”
Interest expense associated with the financing
“approximately $200 million on an annualized basis”
Interest expense related to Amicus financing…
“approximately $200 million”
Total Revenues for FY2026
“$3,875 to $3,925”
Total Revenues Midpoint Growth (Y/Y) for FY2026
“21%”
Metabolic Conditions for FY2026
“$2,725 to $2,775”
Metabolic Conditions Midpoint Growth (Y/Y) for FY2026
“31%”
VOXZOGO Revenue for FY2026
“$1,000 to $1,050”
VOXZOGO Midpoint Growth (Y/Y) for FY2026
“11%”
Other Revenues for FY2026
“$100 to $125”
Metabolic Conditions Revenue for FY2026
“Unchanged”
Non-GAAP Diluted EPS for FY2026
“$4.90 to $5.10”
Non-GAAP Diluted EPS Midpoint Growth (Y/Y) for FY2026
“59%”
Weighted-Average Diluted Shares Outstanding … for FY2026
“approximately 200 million”
Combined company tax rate assumption for Non… for FY2026
“22%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Based on current rates, interest expense associated with the financing is estimated at approximately $200 million on an annualized basis, with Term Loans and Senior Notes scheduled to mature after 2030. Item Provided on May 4, 2026 Updated August 6, 2026 Midpoint Growth (Y/Y) Total Revenues $3,825 to $3,925 $3,875 to $3,925 21% Metabolic Conditions $2,725 to $2,775 Unchanged 31% VOXZOGO $975 to $1,025 $1,000 to $1,050 11% Other Revenues (1) $100 to $125 Unchanged Non-GAAP Diluted EPS (2)(3)(4) $4.85 to $5.05 $4.90 to $5.10 59% (1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definition of Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. (4) Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%. BioMarin will host a conference call and webcast to discuss second quarter 2026 financial results today, Thursday, August 6, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-307-1963 Replay International Dial-in Number: 609-800-9909 Conference ID: 3551298 Conference ID: 3551298 5 About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with g
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.